Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

被引：5
|
作者：
Ramalingam, Suresh S. [1 ]
Saka, Hideo [2 ]
Ahn, Myung-Ju [3 ]
Yu, Helena [4 ]
Horn, Leora [5 ]
Hida, Toyoaki [6 ]
Cantarini, Mireille [7 ]
Verheijen, Remy [7 ]
Wessen, Jonathan [7 ]
Oxnard, Geoffrey [8 ]
Ohe, Yuichiro [9 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan
[3] Samsung Med Ctr, Seoul, South Korea
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Aichi Canc Ctr, Nagoya, Aichi, Japan
[7] Astrazeneca, Global Med Dev, Cambridge, England
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Natl Canc Ctr, Tokyo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT034
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
    Riess, Jonathan W.
    Krailo, Mark D.
    Padda, Sukhmani Kaur
    Groshen, Susan G.
    Wakelee, Heather A.
    Reckamp, Karen L.
    Koczywas, Marianna
    Piotrowska, Zofia
    Steuer, Conor Ernst
    Kim, Chul
    Paweletz, Cloud P.
    Sholl, Lynette M.
    Heavey, Grace
    Kolesar, Jill
    Moscow, Jeffrey
    Janne, Pasi A.
    Lara, Primo
    Newman, Edward M.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors
    Chen, Y-Y.
    Zhu, Q-Q.
    Dai, L-J.
    Ding, Z-Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
    Hartmaier, Ryan
    Han, Ji-Youn
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Cantarini, Mireille
    Frewer, Paul
    Frigault, Melanie M.
    Oxnard, Geoffrey
    CANCER RESEARCH, 2020, 80 (16)
  • [34] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Passaro, A.
    Wang, J.
    Wang, Y.
    Lee, S. -H.
    Melosky, B.
    Shih, J. -Y.
    Wang, J.
    Azuma, K.
    Juan-Vidal, O.
    Cobo, M.
    Felip, E.
    Girard, N.
    Cortot, A. B.
    Califano, R.
    Cappuzzo, F.
    Owen, S.
    Popat, S.
    Tan, J. -l.
    Salinas, J.
    Tomasini, P.
    Gentzler, R. D.
    William, W. N.
    Reckamp, K. L.
    Takahashi, T.
    Ganguly, S.
    Kowalski, D. M.
    Bearz, A.
    MacKean, M.
    Barala, P.
    Bourla, A. B.
    Girvin, A.
    Greger, J.
    Millington, D.
    Withelder, M.
    Xie, J.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Campelo, R. G.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 77 - 90
  • [35] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Moik, F.
    Riedl, J. M.
    Ay, C.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 327 - 327
  • [36] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 169 - 169
  • [37] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S72 - S73
  • [38] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
  • [39] Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC
    De Marinis, F.
    Laktionov, K. K.
    Poltoratskiy, A.
    Egorova, I.
    Hochmair, M.
    Passaro, A.
    Migliorino, M. R.
    Metro, G.
    Gottfried, M.
    Tsoi, D.
    Ostoros, G.
    Rizzato, S.
    Mukhametshina, G. Z.
    Schumacher, M.
    Novello, S.
    Dziadziuszko, R.
    Tang, W.
    Clementi, L.
    Cseh, A.
    Kowalski, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
    Ahn, M.
    Cantarini, M.
    Frewer, P.
    Hawkins, G.
    Peters, J.
    Howarth, P.
    Ahmed, G.
    Sahota, T.
    Hartmaier, R.
    Li-Sucholeiki, X.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S415 - S416
12345